-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ICP-189 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ICP-189 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ICP-189 in Solid Tumor Drug Details: ICP-189 is under development for...
-
Product Insights
Innovations in ICP Monitoring Devices – Global Pipeline Summary
GlobalData's Medical Devices sector report, "Innovations in ICP Monitoring Devices - Global Pipeline Summary" provides comprehensive information about the ICP Monitoring Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The ICP Monitoring Devices report provides key information and data related to: Extensive coverage of the ICP Monitoring Devices under development Review details of major pipeline products which include product description, licensing and collaboration details and other developmental...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orelabrutinib in Nodal Marginal Zone B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orelabrutinib in Nodal Marginal Zone B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orelabrutinib in Nodal Marginal Zone B-Cell Lymphoma Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orelabrutinib in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orelabrutinib in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orelabrutinib in Extranodal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orelabrutinib in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orelabrutinib in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orelabrutinib in Marginal Zone B-cell Lymphoma Drug Details: Orelabrutinib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orelabrutinib in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orelabrutinib in Mantle Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orelabrutinib in Mantle Cell Lymphoma Drug Details: Orelabrutinib (Inokai) acts...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vorasidenib Citrate in Oligodendroglioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vorasidenib Citrate in Oligodendroglioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vorasidenib Citrate in Oligodendroglioma Drug Details: Vorasidenib (AG-881) is under development...
-
Sector Analysis
ICP Monitoring Devices Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
ICP Monitoring Devices Market Report Overview The ICP monitoring devices market was valued at $163.7 million in 2023. The market will grow at a CAGR of more than 2% from 2023 to 2033. In most countries, traumatic brain injury (TBI) is the primary cause of ICP monitoring device usage. Measurement of ICP helps in the detection of brain damage and initiation of therapeutic intervention. ICP monitoring using External Ventricular Drainage (EVD) is considered the gold standard as the technique allows...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zurletrectinib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zurletrectinib in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zurletrectinib in Solid Tumor Drug Details: Zurletrectinib (ICP-723) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Orelabrutinib in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Orelabrutinib in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Orelabrutinib in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details:...